We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Cancer Survival Not Impacted by Red Blood Cells Storage

By LabMedica International staff writers
Posted on 17 Oct 2013
The duration of storage of transfused red blood cells (RBC) has been associated with poor clinical outcomes and may influence cancer patients overall survival or recurrence.

The goal of RBC transfusion is to increase the delivery of oxygen to tissue in vulnerable patients and remains an essential component in the management of medically ill patients, but changes that occur during storage might impair oxygen delivery through a multitude of metabolic and physiologic changes that ensue. More...


Transfusion specialists at the Ottawa Hospital (ON, Canada) analyzed the data from 27,591 patients diagnosed with cancer between January 01, 2000 and December 31, 2005. There were 1,929 patients who had received RBC transfusions within one year from diagnosis. Transfused RBC units were categorized as "new'' if stored for less than 14 days, "intermediate'' if stored between 14 and 28 days and "old'' if stored for more than 28 days.

Overall survival was not associated with duration of storage of transfused RBC with a median survival of 1.2 years for new RBC units, 1.7 years for intermediate storage, and 1.1 years for older RBC units. The mean number of RBC transfusions was 3.42 with 55.5% of patients, receiving between one to two RBC units. Of those patients who received a RBC transfusion within one year from diagnosis, 56.8% were transfused within the first six months. Almost half of the patients requiring transfusion within the first year from diagnosis had either a gastrointestinal or lung malignancy.

Cancer recurrence, defined as recurrence of original malignancy or new metastatic disease, was significantly higher in patients who received a RBC transfusion than those who did not, but recurrence rates were not significantly influenced by the duration of storage of transfused RBC. The data from the study suggests that the duration of storage of transfused RBC has a negligible effect on overall survival (OS) of cancer patients. Not surprisingly, OS was influenced by the patient’s age, advanced stage, chemotherapy and radiation use, cancer-related surgery and cancer recurrence. Although receiving a RBC transfusion was associated with OS in univariate analysis, this was not evident when accounting for confounding variables.

The authors concluded their study highlights the inferior survival of cancer patients requiring RBC transfusions; however, there is no apparent influence of the duration of storage of transfused RBC units on OS or cancer recurrence. They concluded that current RBC transfusion policies that do not differentiate between duration of storage of RBC units are adequate for patients with underlying malignancy. The study was published on July 16, 2013, in the journal Public Library of Science ONE.

Related Links:

Ottawa Hospital



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
New
Automated Urinalysis Solution
UN-9000
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.